United States · FDA National Drug Code directory
Skyrizi
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0074-1070_388f783d-f41e-4f04-bf64-ec637fe05bdf
- Product NDC
- 0074-1070
- Form
- KIT
- Composition / generic term
- Risankizumab-rzaa
- Labeler
- AbbVie Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20220616
- Source listing expiry
- 20271231
Source-listed ingredients
Separate ingredient quantities are not available in this snapshot. Any composition term above is preserved as source text.
These values do not establish equivalence or a dose recommendation.
Packages
- 1 KIT in 1 CARTON (0074-1070-01) * 2.4 mL in 1 CARTRIDGE (0074-1069-02) * 2.4 mL in 1 CARTRIDGE (0074-1069-01) · 0074-1070-01
- 1 KIT in 1 CARTON (0074-1070-02) * 2.4 mL in 1 CARTRIDGE (0074-1069-02) * 2.4 mL in 1 CARTRIDGE (0074-1069-01) · 0074-1070-02
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →